Publicaciones en colaboración con investigadores/as de Hospital Universitari de Bellvitge (26)

2024

  1. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

    The Lancet, Vol. 403, Núm. 10437, pp. 1649-1659

  2. Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab

    Breast Cancer Research and Treatment, Vol. 205, Núm. 3, pp. 589-598

  3. Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study

    ESMO Open, Vol. 9, Núm. 10

  4. Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial

    ESMO Open, Vol. 9, Núm. 9

2023

  1. A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer

    Frontiers in Oncology, Vol. 13

  2. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

    Annals of Oncology, Vol. 34, Núm. 9, pp. 783-795

2021

  1. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

    The Lancet Oncology, Vol. 22, Núm. 6, pp. 858-871

  2. The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-Analyses Evaluating the Efficacy and Safety of Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis”

    Frontiers in Molecular Biosciences, Vol. 8

  3. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

    The Lancet Oncology, Vol. 21, Núm. 11, pp. 1455-1464

  2. Atezolizumab in the treatment of metastatic triple-negative breast cancer

    Expert Opinion on Biological Therapy, Vol. 20, Núm. 9, pp. 981-989

  3. Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design

    Contemporary Clinical Trials Communications, Vol. 20

  4. The persistent breach between evidence and practice in the prevention of surgical site infection. Qualitative study

    International Journal of Surgery

  5. The value of case reports in systematic reviews from rare diseases. The example of enzyme replacement therapy (ERT) in patients with mucopolysaccharidosis type II (MPS-II)

    International Journal of Environmental Research and Public Health, Vol. 17, Núm. 18, pp. 1-16

2019

  1. Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases

    Orphanet Journal of Rare Diseases, Vol. 14, Núm. 1

  2. Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

    Aging, Vol. 11, Núm. 9, pp. 2874-2888

  3. Neoadjuvant metformin added to systemic therapy decreases the proliferative capacity of residual breast cancer

    Journal of Clinical Medicine, Vol. 8, Núm. 12

  4. The C allele of ATM rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin

    Frontiers in Oncology, Vol. 9, Núm. MAR

2018

  1. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study

    Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704

  2. Perspectives on preoperative systemic treatment and breast conservative surgery: One step forward or two steps back?

    Breast, Vol. 41, pp. 133-135